Drugs / GMZ2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00703066 | Jun 2008 → Jul 2009 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 1 | NCT00424944 | Jun 2007 → Jul 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 1 | NCT00397449 | Oct 2006 → Dec 2007 | malaria | European Vaccine Initiative | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMZ 2 | “GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage...” PMID 21829466 ↗ Jul 20113“Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine” NCT00424944 ↗ |
| Modality | Vaccine | “GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)” NCT00397449 ↗ |